Overall, the development of different in vivo treatments promoting TDP-43 nuclear exit and cytoplasmic aggregation represents an interesting area for future modelling of sporadic ALS, that could be aided by the use of predisposed models, such as presymptomatic TDP-43 mutant mice, for developing multiple hits models. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.